The main purpose of this legislation is to modify the Medicare program by exempting certain drugs from the manufacturer discount program under Medicare Part D. This change aims to ensure that patients have better access to essential medications that may not fit within the current discount structure. Key provisions of this legislation include the amendment of existing law to specify that certain orally administered drugs will not be subject to the manufacturer discount program.